Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Favié, Laurent MaMurk, Jean-Luc
Meijer, Adam
Nijstad, A Laura
van Maarseveen, Erik M
Sikma, Maaike A
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza.Published in
Antivir Ther 2018; 23(5):457-61Publiekssamenvatting
Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous hemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.DOI
10.3851/IMP3210PMID
29185991ae974a485f413a2113503eed53cd6c53
10.3851/IMP3210
Scopus Count
Collections
Related articles
- Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza.
- Authors: Wang Y, Zhong W, Salam A, Tarning J, Zhan Q, Huang JA, Weng H, Bai C, Ren Y, Yamada K, Wang D, Guo Q, Fang Q, Tsutomu S, Zou X, Li H, Gillesen A, Castle L, Chen C, Li H, Zhen J, Lu B, Duan J, Guo L, Jiang J, Cao R, Fan G, Li J, Hayden FG, Wang C, Horby P, Cao B
- Issue date: 2020 Dec
- Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
- Authors: Takashita E, Ejima M, Ogawa R, Fujisaki S, Neumann G, Furuta Y, Kawaoka Y, Tashiro M, Odagiri T
- Issue date: 2016 Aug
- [Favipiravir, a new concept of antiviral drug against influenza viruses].
- Authors: Reina J, Reina N
- Issue date: 2017 Apr
- In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
- Authors: Tarbet EB, Vollmer AH, Hurst BL, Barnard DL, Furuta Y, Smee DF
- Issue date: 2014 Jun
- Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection.
- Authors: Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, Pan J, Zheng J, Lu B, Guo L, Wang C, Cao B
- Issue date: 2020 Apr 27